Valine

Evidence Level: L4

Predicted Indications: 10

Valine

Pharmacist Assessment Report

Valine: From Nutritional/Metabolic Supplementation to Sclerosing Cholangitis

One-Sentence Summary

Valine is an essential branched-chain amino acid (BCAA) supplied in Australia as a dietary management product for metabolic conditions. The TxGNN model predicts it may be relevant to sclerosing cholangitis, but this rests on a model score alone. No clinical trials are registered, and only 2 publications were retrieved, both associative (a cohort study and a Mendelian randomization study). There is no evidence that valine treats the disease.

Quick Overview

Item	Content
Original Indication	Not stated in the data compiled for this report. The ARTG entries include a valine-only product (Valine 50) and a combination metabolic formula (MMA/PA Anamix Junior), the latter name suggesting use in methylmalonic and propionic acidaemia (inferred from the product name, not from approved indication text)
Predicted New Indication	Sclerosing cholangitis
TxGNN Prediction Score	0.9942
Evidence Level	L4
Australia Market Status	Listed on the PBS Schedule (2 of 2 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	2 (valid: 2)
Recommended Decision	Hold (research question only)

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Valine is a branched-chain amino acid, and the data compiled for this report do not include a formal mechanism of action.

Altered amino acid profiles, including BCAA and aromatic amino acid ratios, have been described in cholestatic liver disease. A 2024 Mendelian randomization study examined causal relationships between blood metabolites and cholestatic liver diseases (primary biliary cholangitis and primary sclerosing cholangitis). The link is metabolic and associative. There is no evidence that giving valine changes the course of sclerosing cholangitis. The 2005 paper concerns plasma tyrosine and fatigue, not valine therapy.

The high model score should therefore be treated as a hypothesis-generating signal only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39015781	2024	Mendelian randomization	Frontiers in Medicine	Examined causal links between blood metabolites and primary biliary cholangitis and primary sclerosing cholangitis
15790420	2005	Cohort	BMC Gastroenterology	Examined amino acid patterns, particularly plasma tyrosine, in relation to fatigue in PBC and PSC. Does not test valine therapy

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 9135T	Valine 50	Oral powder sachets, 4 g (50 mg valine), 30	Not stated
ARTG 10730R	MMA/PA Anamix Junior	Oral powder sachets, 18 g, 30	Not stated

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold (research question only)

Rationale: The prediction has no clinical trial support, and the two retrieved publications are associative and do not test valine as a treatment. The data compiled for this report contain no mechanism of action and no safety information, so the candidate cannot progress to safety screening.

To proceed, the following is needed:

Approved indication text and Product Information (warnings, contraindications) for both ARTG entries
Mechanism of action data, and a plausible rationale for why valine supplementation would affect sclerosing cholangitis rather than merely correlate with it
Preclinical or mechanistic studies testing valine or BCAA supplementation in cholestatic liver disease models
Assessment of route and formulation suitability, given the current products are oral dietary-management powders designed for metabolic disorders

Note on other predictions: The other top-ranked predictions (angle-closure glaucoma, hyperthyroidism, aqueous misdirection, traumatic glaucoma, neovascular glaucoma, glaucomatous optic disc atrophy, thyroid hormone resistance, hyperthyroxinaemia) have even weaker support. Several literature matches appear to be artefacts of “Val” mutation nomenclature (for example TSH receptor and thyroid hormone receptor beta variants) rather than studies of valine as a drug. The hyperthyroidism predictions have only indirect, associative BCAA metabolism data. One prediction (“obsolete bundle branch block”) is an obsolete ontology term and should likely be excluded.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.